Topical pharmacotherapy for skin cancer: part II. Clinical applications.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24831325.
- Also identified by DOI 10.1016/j.jaad.2013.12.037.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of the paper is to provide an in-depth, evidence-based analysis of the clinical use of topical treatments for skin cancer. A comprehensive review of topical drugs has been performed, including 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, retinoids, resiquimod, piroxicam, dobesilate, and betulinic acid. The evaluated studies were rated according to their level of evidence level (I-V), as indicated by recent guidelines for evidence-based medicine, The Oxford 2011 Levels of Evidence. Therapeutic response is generally related to tumor type, extent, and localization, and also to patient compliance. Careful patient selection is required in order to achieve the desired goal of complete tumor clearance.
Medical subject headings
- Antineoplastic Agents
- Keratosis, Actinic
- Neoplasm Recurrence, Local
- Skin Neoplasms